MCL1 and acute myeloid leukemia: The phase 1, first-in-human MCL1 inhibitor trial of AZD5991 in patients with AML or myelodysplastic syndromes (MDSs) showed a high incidence of troponin elevation and a low overall response rate, with dose-limiting toxicities and four treatment-related deaths [89].